Your browser doesn't support javascript.
loading
Antibody response durability following three-dose COVID-19 vaccination in people with HIV receiving suppressive ART
Hope R. Lapointe; Francis Mwimanzi; Peter K. Cheung; Yurou Sang; Fatima Yaseen; Sarah Speckmaier; Evan Barad; Nadia Moran-Garcia; Sneha Datwani; Maggie C. Duncan; Rebecca Kalikawe; Siobhan Ennis; Landon Young; Bruce Ganase; F. Harrison Omondi; Gisele Umviligihozo; Winnie Dong; Junine Toy; Paul Sereda; Laura Burns; Cecilia T. Costiniuk; Curtis Cooper; Aslam H. Anis; Victor Leung; Daniel T. Holmes; Mari L. DeMarco; Janet Simons; Malcolm Hedgcock; Natalie Prystajecky; Christopher F. Lowe; Marc G. Romney; Rolando Barrios; Silvia Guillemi; Chanson J. Brumme; Julio S.G. Montaner; Mark Hull; Marianne Harris; Masahiro Niikura; Mark A. Brockman; Zabrina L. Brumme.
Afiliação
  • Hope R. Lapointe; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
  • Francis Mwimanzi; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
  • Peter K. Cheung; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
  • Yurou Sang; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
  • Fatima Yaseen; Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, Canada
  • Sarah Speckmaier; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
  • Evan Barad; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
  • Nadia Moran-Garcia; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
  • Sneha Datwani; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
  • Maggie C. Duncan; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
  • Rebecca Kalikawe; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
  • Siobhan Ennis; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
  • Landon Young; Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada
  • Bruce Ganase; AIDS Research Program, St. Paul's Hospital, Vancouver, Canada
  • F. Harrison Omondi; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
  • Gisele Umviligihozo; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
  • Winnie Dong; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
  • Junine Toy; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
  • Paul Sereda; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
  • Laura Burns; Department of Pathology and Laboratory Medicine, Providence Health Care, Vancouver, Canada
  • Cecilia T. Costiniuk; Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre and Research Institute of the McGill University Health Centre
  • Curtis Cooper; Department of Medicine, University of Ottawa, Ottawa, Canada; Ottawa Hospital Research Institute, Ottawa, Canada
  • Aslam H. Anis; School of Population and Public Health, University of British Columbia, Vancouver, Canada; CIHR Canadian HIV Trials Network, University of British Columbia, Van
  • Victor Leung; Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada; Department of Pathology and Laboratory Medicine, Providence Health Care,
  • Daniel T. Holmes; Department of Pathology and Laboratory Medicine, Providence Health Care, Vancouver, Canada; Department of Pathology and Laboratory Medicine, University of Briti
  • Mari L. DeMarco; Department of Pathology and Laboratory Medicine, Providence Health Care, Vancouver, Canada; Department of Pathology and Laboratory Medicine, University of Briti
  • Janet Simons; Department of Pathology and Laboratory Medicine, Providence Health Care, Vancouver, Canada; Department of Pathology and Laboratory Medicine, University of Briti
  • Malcolm Hedgcock; Spectrum Health, Vancouver, Canada
  • Natalie Prystajecky; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada; British Columbia Centre for Disease Control Public Health La
  • Christopher F. Lowe; Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada; Department of Pathology and Laboratory Medicine, Providence Health Care,
  • Marc G. Romney; Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada; Department of Pathology and Laboratory Medicine, Providence Health Care,
  • Rolando Barrios; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada; 0 School of Population and Public Health, University of British Columbia, Vancouver, Cana
  • Silvia Guillemi; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada; Department of Family Practice, Faculty of Medicine, University of British Columbia, Cana
  • Chanson J. Brumme; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada; Department of Medicine, University of British Columbia, Vancouver, Canada
  • Julio S.G. Montaner; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada; Department of Medicine, University of British Columbia, Vancouver, Canada
  • Mark Hull; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada; Department of Medicine, University of British Columbia, Vancouver, Canada
  • Marianne Harris; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada; Department of Family Practice, Faculty of Medicine, University of British Columbia, Canad
  • Masahiro Niikura; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
  • Mark A. Brockman; Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, Canada; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
  • Zabrina L. Brumme; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
Preprint em Inglês | medRxiv | ID: ppmedrxiv-22281912
ABSTRACT
BackgroundLimited data exist regarding longer-term antibody responses following three-dose COVID-19 vaccination, and the impact of a first SARS-CoV-2 infection during this time, in people living with HIV (PLWH) receiving suppressive antiretroviral therapy (ART). We quantified wild-type-(WT), Omicron BA.1- and Omicron BA.5-specific responses up to six months post-third dose in 64 PLWH and 117 controls who remained COVID-19-naive or experienced their first SARS-CoV-2 infection during this time. DesignLongitudinal observational cohort. MethodsWe quantified WT- and Omicron-specific Anti-Spike receptor-binding domain IgG concentrations, ACE2 displacement activities and live virus neutralization at one, three and six months post-third vaccine dose. ResultsThird doses boosted all antibody measures above two-dose levels, but BA.1-specific responses remained significantly lower than WT-specific ones, with BA.5-specific responses lower still. Serum IgG concentrations declined at similar rates in COVID-19-naive PLWH and controls post-third dose (median WT- and BA.1-specific half-lives were between 66-74 days for both groups). Antibody function also declined significantly yet comparably between groups six months post-third dose, BA.1-specific neutralization was undetectable in >80% of COVID-19 naive PLWH and >90% of controls. Breakthrough SARS-CoV-2 infection boosted antibody concentrations and function significantly above vaccine-induced levels in both PLWH and controls, though BA.5-specific neutralization remained significantly poorer than BA.1 even post-breakthrough. ConclusionsFollowing three-dose COVID-19 vaccination, antibody response durability in PLWH receiving ART is comparable to controls. PLWH also mounted strong responses to breakthrough infection. Due to temporal response declines however, COVID-19-naive individuals, regardless of HIV status, would benefit from a fourth dose within 6 months of their third.
Licença
cc_by_nc_nd
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Cohort_studies / Experimental_studies / Estudo observacional / Estudo prognóstico / Rct Idioma: Inglês Ano de publicação: 2022 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Cohort_studies / Experimental_studies / Estudo observacional / Estudo prognóstico / Rct Idioma: Inglês Ano de publicação: 2022 Tipo de documento: Preprint
...